Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs ABL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABL Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–0 Matrix Metrics)

ABL Overall Winner 6-Pillar Tally: VVOS 0 – 6 ABL Matrix Metrics: VVOS 0 – 9 ABL

As of Nov 20, 2026, Abacus Global Management, Inc. (ABL) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas ABL carries 61.3/100 (BUY) at $8.47 (8.6x Forward P/E, 35.6% operating margin).

  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile ABL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs ABL
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
ABL NASDAQ Head-to-Head Winner
Abacus Global Management, Inc. Class A Common Stock
Investment Advice
$8.47
-0.35% 1D
Market Cap $830.9M
TTM Revenue $87M
Forward P/E 8.6x
Beta / 30D Vol 1.19β · 48% Vol
Unified Composite Score
61.3 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (13.4% over 20 days), RSI 68
RSI-14: 67.8 · SMA20: $7.89 · SMA50: $6.67

6-Pillar Scorecard Institutional Category Breakdown (VVOS 0 – 6 ABL)

Columns: Metric · VVOS · ABL
1. Valuation Multiples ABL
Forward P/E N/M 8.6x
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x 9.6x
2. Growth & Scale ABL
Revenue Growth (YoY) +34.9% +123.7%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $21M $87M
Market Cap $1.9M $830.9M
3. Profitability & Quality ABL
Gross Margin 61.9% 87.5%
Operating Margin -107.9% 35.6%
Net Profit Margin -121.8% 5.6%
Return on Equity (ROE) -8585.3% 3.2%
4. Balance Sheet & Cash Flow ABL
Cash Generation (TTM) -$21M EBITDA $32M EBITDA
Cash Flow Margin -99.3% EBITDA Mgn 36.7% EBITDA Mgn
Net Cash / Leverage -8585.3% ROE $4.45 Book/Sh · 3.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABL
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) 52.0% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ABL
OpEx & R&D Intensity N/A 51.9% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Insurance - Life Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (0) vs ABL (9)
Institutional Metric VVOS ABL Criterion Row Edge
Market Capitalization
Scale
$1.9M $830.9M Larger Scale ABL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M 8.6x Lower Multiple ABL
Revenue Growth (YoY)
Growth
+34.9% +123.7% Higher Growth ABL
Operating Margin (TTM)
Profitability
-107.9% 35.6% Higher Margin ABL
Net Profit Margin
Profitability
-121.8% 5.6% Higher Margin ABL
Return on Equity (ROE)
Capital Efficiency
-8585.3% 3.2% Higher ROE ABL
52-Week Range Position
Momentum
0% ($0–$3) 77% ($5–$10) Stronger Trend ABL
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 1.19β · 48% Vol Lower Realized Risk ABL
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 61.3 / 100 (BUY) Higher Composite ABL
Trailing 12M Revenue (USD)
Operating Scale
$21M $87M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% 87.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) $32M EBITDA ($4.45 Book/Sh · 3.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABL +38.89 pp
VVOS: -9.38% · ABL: +29.51%
3M Horizon ABL +55.62 pp
VVOS: -13.98% · ABL: +41.64%
6M Horizon ABL +55.62 pp
VVOS: -13.98% · ABL: +41.64%
1Y Horizon ABL +55.62 pp
VVOS: -13.98% · ABL: +41.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VVOS vs ABL. Trailing 12-month operating profitability (VVOS -107.9% vs ABL 35.6%) and valuation multiples (VVOS N/M vs ABL 8.6x Forward P/E) are benchmarked directly in Pillar 4 below.

VVOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.9%
Op. Margin-107.9%
ROE / Fwd P/E-8585.3% · N/M
ABL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$87M
Gross Margin87.5%
Op. Margin35.6%
ROE / Fwd P/E3.2% · 8.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 52.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABL Moat Profile High-Margin Pricing Power Moat
Insurance - Life Operator
Competes within the Insurance - Life value chain with $830.9M market capitalization and 35.6% operating margin.
OpEx & R&D Reinvestment 51.9% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs ABL Key Questions & Quantitative Answers

As of Nov 20, 2026, Abacus Global Management, Inc. (ABL) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas ABL carries 61.3/100 (BUY) at $8.47 (8.6x Forward P/E, 35.6% operating margin). Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile ABL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABL leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with ABL at +123.7% YoY revenue growth and N/A YoY earnings growth on $87M TTM revenue (87.5% gross margin, 35.6% operating margin). On trailing 12-month operating scale, VVOS generates $21M in USD-normalized revenue versus $87M for ABL. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus 51.9% of Rev ($45M) (0 disclosures) for ABL.

ABL screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas ABL trades at 8.6x Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (36.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus ABL (3.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, ABL carries 52.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.